Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dosage of Caspofungin in Critically Ill Patients
NCT01994096Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2013
- Primary completion
- Oct 2015
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of caspofungin in invasive candidiasis, sponsored by University Medical Center Groningen. Started Nov 2013; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on NCT01994096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994096.